Drugs / CD19/CD20 dual-targeted CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07093086 | Nov 2024 → Nov 2026 | B-cell neoplasm | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/CD20 dual-targeted CAR-T cells | “Patients will receive a regimen combining CD19/CD22 dual-targeted CAR-T cells with CD19/CD20 dual-targeted CAR-T cells; investigators may administer them sequentially according...” NCT07093086 ↗ |
| Modality | Cell therapy | “CD19/CD20 dual-targeted CAR-T cells” NCT07093086 ↗ |
| Target | CD19 | “CD19/CD20 dual-targeted CAR-T cells” NCT07093086 ↗ |